Zeke Capital Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | $3.03M | Sell |
12,770
-1,524
| -11% | -$362K | 0.2% | 51 |
|
|
2022
Q3 | $2.86M | Hold |
14,294
| – | – | 0.21% | 53 |
|
|
2022
Q2 | $2.08M | Sell |
14,294
-1,339
| -9% | -$195K | 0.14% | 74 |
|
|
2022
Q1 | $2.55M | Buy |
15,633
+1,278
| +9% | +$209K | 0.13% | 76 |
|
|
2021
Q4 | $2.43M | Buy |
14,355
+1,274
| +10% | +$216K | 0.14% | 50 |
|
|
2021
Q3 | $2.47M | Hold |
13,081
| – | – | 0.14% | 54 |
|
|
2021
Q2 | $2.22M | Buy |
+13,081
| New | +$2.22M | 0.14% | 62 |
|
|
2020
Q1 | – | Sell |
-5,309
| Closed | -$611K | – | 247 |
|
|
2019
Q4 | $611K | Sell |
5,309
-1,261
| -19% | -$145K | 0.05% | 335 |
|
|
2019
Q3 | $528K | Sell |
6,570
-1,438
| -18% | -$116K | 0.05% | 347 |
|
|
2019
Q2 | $581K | Buy |
8,008
+733
| +10% | +$53.2K | 0.05% | 321 |
|
|
2019
Q1 | $680K | Sell |
7,275
-2,429
| -25% | -$227K | 0.06% | 285 |
|
|
2018
Q4 | $708K | Buy |
9,704
+2,351
| +32% | +$172K | 0.07% | 262 |
|
|
2018
Q3 | $644K | Buy |
+7,353
| New | +$644K | 0.05% | 341 |
|